{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:27:44Z","timestamp":1793845664045,"version":"4.6.1"},"reference-count":34,"publisher":"Grigore T. Popa University of Medicine and Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Clin Cases"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in patients with inflammatory bowel disease (IBD), but accurate, disease-specific predictive tools are lacking. This study aimed to identify key risk factors and develop tailored prediction models for MASLD in IBD patients. Material and methods: In a retrospective\u2013prospective cohort of 157 IBD patients (Ulcerative colitis: 51.6%; Crohn\u2019s disease: 48.4%), we performed serial clinical, laboratory, and imaging evaluations across four clinical visits. Hepatic steatosis was assessed using transient elastography with controlled attenuation parameter (CAP &gt;273 dB\/m). Logistic regression identified independent risk factors for MASLD, leading to the development of an additive clinical score and a logistic regression-based score. Their diagnostic performances were compared with established indices (Hepatic steatosis index (HSI), Fatty liver index (FLI)). Results: MASLD was diagnosed in 37 patients (23.5%). Independent predictors included smoking (OR 3.55), dyslipidemia (OR 2.82), hypertension (OR 2.77), prolonged IBD duration, higher BMI, male sex, frequent disease flares, and corticosteroid exposure. The additive score (cut-off \u22653) showed good sensitivity (36.1%) but high specificity (94%). The logistic score (cut-off \u22653.5) achieved moderate specificity (45.3%) with excellent sensitivity (86.1%). Both models outperformed HSI (AUC 0.671) and FLI (AUC 0.701). CAP remained the most accurate tool (AUC 0.957). Conclusion: MASLD is highly prevalent in IBD patients, driven by both metabolic and disease-specific factors. The proposed clinical scores provide simple, accessible tools for early risk stratification, potentially guiding personalized surveillance in settings lacking advanced imaging technologies.<\/jats:p>","DOI":"10.22551\/2025.48.1203.10321","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:06:40Z","timestamp":1756721200000},"page":"102-109","source":"Crossref","is-referenced-by-count":6,"title":["MASLD risk prediction in IBD: development of two tailored clinical scores"],"prefix":"10.22551","volume":"12","author":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania; Institute of Gastroenterology and Hepatology, \u201cSf. Spiridon\u201d University Hospital, Iasi, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-6559","authenticated-orcid":false,"given":"Remus","family":"Stafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-0663","authenticated-orcid":false,"given":"Robert","family":"Nastasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania; Institute of Gastroenterology and Hepatology, \u201cSf. Spiridon\u201d University Hospital, Iasi, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-4049","authenticated-orcid":false,"given":"Carol","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Institute of Gastroenterology and Hepatology, \u201cSf. Spiridon\u201d University Hospital, Iasi, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9837","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"1. Friedrich M, Pohin M, Powrie F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity. 2019 Apr 16;50(4):992-1006. doi: 10.1016\/j.immuni.2019.03.017. PMID: 30995511.","DOI":"10.1016\/j.immuni.2019.03.017"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Hracs L, Windsor JW, Gorospe J, et al. Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun;642(8067):458-466. doi: 10.1038\/s41586-025-08940-0. PMID: 40307548; PMCID: PMC12158780.","DOI":"10.1038\/s41586-025-08940-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016\/S0140-6736(17)32448-0. Erratum in: Lancet. 2020 Oct 3;396(10256):e56. doi: 10.1016\/S0140-6736(20)32028-6. PMID: 29050646.","DOI":"10.1016\/S0140-6736(20)32028-6"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Shouval DS, Rufo PA. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. JAMA Pediatr. 2017 Oct 1;171(10):999-1005. doi: 10.1001\/jamapediatrics.2017.2571. PMID: 28846760.","DOI":"10.1001\/jamapediatrics.2017.2571"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019 Jan;94(1):155-165. doi: 10.1016\/j.mayocp.2018.09.013. PMID: 30611442; PMCID: PMC6386158.","DOI":"10.1016\/j.mayocp.2018.09.013"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66. doi: 10.1038\/s41575-020-00360-x. PMID: 33033392; PMCID: PMC7542092.","DOI":"10.1038\/s41575-020-00360-x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Danpanichkul P, Suparan K, Dutta P, et al. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024 Sep; 158:155958. doi: 10.1016\/j.metabol.2024.155958. PMID: 38942169.","DOI":"10.1016\/j.metabol.2024.155958"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Danpanichkul P, Auttapracha T, Sukphutanan B, et al. The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis. Am J Gastroenterol. 2024 Jun 1;119(6):1177-1180. doi: 10.14309\/ajg.0000000000002819. PMID: 38900306.","DOI":"10.14309\/ajg.0000000000002819"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. N\u00fa\u00f1ez F P, Castro F, Mezzano G, et al. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol. 2022 Feb 27;14(2):319-337. doi: 10.4254\/wjh.v14.i2.319. PMID: 35317174; PMCID: PMC8891676.","DOI":"10.4254\/wjh.v14.i2.319"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Invest. 2025 Apr 1;135(7):e186423. doi: 10.1172\/JCI186423. PMID: 40166938; PMCID: PMC11957707.","DOI":"10.1172\/JCI186423"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb 1;13(2):144-164. doi: 10.1093\/ecco-jcc\/jjy113. PMID: 30137275.","DOI":"10.1093\/ecco-jcc\/jjy113"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Khanna R, Son S, Zou G, Roshanov PS. Estimation of the Harvey Bradshaw Index from the Patient-Reported Outcome 2 in Crohn's Disease: Results Based on a Large Scale Randomized Controlled Trial. Inflamm Bowel Dis. 2024 Dec 4: izae281. doi: 10.1093\/ibd\/izae281. Erratum in: Inflamm Bowel Dis. 2025 Feb 11: izaf014. doi: 10.1093\/ibd\/izaf014. PMID: 39656815.","DOI":"10.1093\/ibd\/izaf014"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Jia S, Zhou J, Zhang Q, et al. Clinical research of fibroscan - TE-CAP at noninvasive diagnosis of hepatic steatosis in children. Clinics (Sao Paulo). 2024 May 27; 79:100387. doi: 10.1016\/j.clinsp.2024.100387. PMID: 38805982; PMCID: PMC11152890.","DOI":"10.1016\/j.clinsp.2024.100387"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010 Feb;51(2):454-62. doi: 10.1002\/hep.23312. PMID: 20101745.","DOI":"10.1002\/hep.23312"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Frank D, DeBenedetti AF, Volk RJ, et al. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race\/ethnic groups. J Gen Intern Med. 2008 Jun;23(6):781-7. doi: 10.1007\/s11606-008-0594-0. PMID: 18421511; PMCID: PMC2517893.","DOI":"10.1007\/s11606-008-0594-0"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Rinella, ME, Lazarus, JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016\/j.aohep.2023.101133. PMID: 37364816.","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Khakoo NS, Ioannou S, Khakoo NS, Vedantam S, Pearlman M. Impact of Obesity on Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2022 Jan;24(1):26-36. doi: 10.1007\/s11894-022-00840-x. PMID: 35150406.","DOI":"10.1007\/s11894-022-00840-x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022 Apr;55(8):894-907. doi: 10.1111\/apt.16879. PMID: 35274325; PMCID: PMC9297733.","DOI":"10.1111\/apt.16879"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Navarro P, Guti\u00e9rrez-Ram\u00edrez L, Tejera-Mu\u00f1oz A, Arias \u00c1, Lucendo AJ. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients. 2023 Oct 24;15(21):4507. doi: 10.3390\/nu15214507. PMID: 37960160; PMCID: PMC10648917.","DOI":"10.3390\/nu15214507"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Sartini A, Gitto S, Villa E. Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients? Dig Dis Sci. 2017 Sep;62(9):2604-2606. doi: 10.1007\/s10620-017-4665-0. PMID: 28676901.","DOI":"10.1007\/s10620-017-4665-0"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2023 Feb;21(2):406-414.e7. doi: 10.1016\/j.cgh.2022.01.039. PMID: 35124272.","DOI":"10.1016\/j.cgh.2022.01.039"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Zhang Q, Xu F, Wang Z, et al. Long-Term Risk of Inflammatory Bowel Disease With MASLD: A Large-Scale Prospective Cohort Study in UK Biobank. J Gastroenterol Hepatol. 2025 Apr;40(4):855-865. doi: 10.1111\/jgh.16880. PMID: 39828371.","DOI":"10.1111\/jgh.16880"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Xu J, Li Y, Feng Z, Chen H. Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy. Cells. 2025 Feb 4;14(3):221. doi: 10.3390\/cells14030221. PMID: 39937012; PMCID: PMC11816580.","DOI":"10.3390\/cells14030221"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Chen BC, Weng MT, Chang CH, Huang LY, Wei SC. Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study. Sci Rep. 2022 May 10;12(1):7665. doi: 10.1038\/s41598-022-11860-y. PMID: 35538186; PMCID: PMC9090732.","DOI":"10.1038\/s41598-022-11860-y"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Derella CC, Tingen MS, Blanks A, et al. Smoking cessation reduces systemic inflammation and circulating endothelin-1. Sci Rep. 2021 Dec 16;11(1):24122. doi: 10.1038\/s41598-021-03476-5. PMID: 34916543; PMCID: PMC8677816.","DOI":"10.1038\/s41598-021-03476-5"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Qiu X, Shen S, Jiang N, et al. Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017-2020. BMC Gastroenterol. 2025 Jan 29;25(1):42. doi: 10.1186\/s12876-025-03625-4. PMID: 39881239; PMCID: PMC11776320.","DOI":"10.1186\/s12876-025-03625-4"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Saroli Palumbo C, Restellini S, Chao CY, et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133. doi: 10.1093\/ibd\/izy200. PMID: 29889226.","DOI":"10.1093\/ibd\/izy200"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Chen YT, Chen TI, Yang TH, et al. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes. Am J Gastroenterol. 2024 Nov 1;119(11):2241-2250. doi: 10.14309\/ajg.0000000000002778. PMID: 38534155; PMCID: PMC11524626.","DOI":"10.14309\/ajg.0000000000002778"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016\/j.jhep.2020.03.039. PMID: 32278004.","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016 Dec;65(12):2035-2044. doi: 10.1136\/gutjnl-2016-312729. PMID: 27802157.","DOI":"10.1136\/gutjnl-2016-312729"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411. doi: 10.1038\/s41575-018-0011-z. Erratum in: Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):785. doi: 10.1038\/s41575-018-0031-8. PMID: 29748586; PMCID: PMC6319369.","DOI":"10.1038\/s41575-018-0031-8"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Abdelhameed F, Mustafa A, Kite C, et al. Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications. Livers. 2025; 5(1):11. doi: 10.3390\/livers5010011","DOI":"10.3390\/livers5010011"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Quesada-V\u00e1zquez S, Bone C, Saha S, et al. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination. Int J Mol Sci. 2022 Nov 8;23(22):13675. doi: 10.3390\/ijms232213675. PMID: 36430154; PMCID: PMC9692973.","DOI":"10.3390\/ijms232213675"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Fousekis FS, Katsanos KH, Theopistos VI, et al. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study. BMC Gastroenterol. 2019 Apr 3;19(1):48. doi: 10.1186\/s12876-019-0967-3. PMID: 30943899; PMCID: PMC6446300.\"","DOI":"10.1186\/s12876-019-0967-3"}],"container-title":["Archive of Clinical Cases"],"original-title":[],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:11:16Z","timestamp":1756721476000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalcases.eu\/index.php\/acc\/article\/view\/1193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,15]]}},"URL":"https:\/\/doi.org\/10.22551\/2025.48.1203.10321","relation":{},"ISSN":["2360-6975","2360-6975"],"issn-type":[{"value":"2360-6975","type":"print"},{"value":"2360-6975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}